With the help of a 2016 Lori Milken–PCF Young Investigator Award from the Prostate Cancer Foundation, Loredana Puca, Ph.D., is studying the genomic characteristics of neuroendocrine prostate cancer and whether it might be possible to develop an epigenetic therapy to treat it. Read more
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation’s top healthcare institutions in supporting revised vaccination guidelines from the Centers for Disease Control and Prevention (CDC) for the human papillomavirus (HPV). Read more
Lewis C. Cantley, Ph.D., and Kristy Richards, Ph.D., M.D. are collaborating to revamp the ways cancer drugs can be researched, tested and approved. Read more
An Ithaca-NYC team has developed a modular immune organoid that can replicate the anatomical structures found within lymph nodes to mimic the early stages of a germinal center, where B cell differentiation and initiation of immunological responses take place during infection. Read more
An Ithaca-NYC team has found that the stiffening of the matrix surrounding a metastatic tumor plays a key role in the vascular makeup of the tumor that promotes tumor growth and mobility by keeping drugs out. Read more
The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Jim Hu, M.D. Read more
Linda Vahdat, M.D., is turning to the public to help fund a trial for a new triple negative breast cancer treatment involving a simple oral medication that reduces copper levels in the patient’s body Read more
Ninety-five percent of patients with advanced cancer have an insufficient understanding of their prognosis and are ill-equipped to make informed end-of-life care decisions, according to a study by Holly Prigerson, Ph.D., and colleagues. Read more
A simple blood test may better predict which patients diagnosed with liver cancer will experience disease recurrence, according to new research from Weill Cornell Medicine doctors. Read more
The tumor microenvironment can determine whether cancer cells become aggressive cancer stem cells that are resistant to treatment and cause cancers to come back after therapy, according to a new study by a team of researchers led by Shahin Rafii. Read more
